H.C. Wainwright lowered the firm’s price target on TC Biopharm (TCBP) to $3 from $7 and keeps a Buy rating on the shares. The firm updated its model to reflect launch timing, market trends, and capital structure changes.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCBP: